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Summary
Carcinoma of the rectum represents a major public health issue, affects many patients and causes controversies about 
the optimal treatment modalities and their timing. Based on the results of numerous studies neoadjuvant chemoradiother-
apy is newly often favorised in all localized tumors, except the earliest ones. With this multimodal approach a significant 
tumor regression with acceptable side-effects can be achieved and later surgical procedures alleviated or even omitted in 
highly selected cases.
In this review paper the latest data on rectal cancer treatment and expected future research ideas are explained and 
discussed in detail.
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LIJE^ENJE KARCINOMA REKTUMA
Sa`etak
Rak rektum predstavlja zna~ajan javnozdravstveni problem, zbog brojnosti pacijenata i nedoumica oko optimalnog 
slijeda raznih vidova lije~enja. Na temelju rezultata brojnih studija neoadjuvantna kemoradioterapija se u zadnje vrijeme 
pretpostavlja u lije~enju lokaliziranih tumora, izuzev najranijih stadija. Takvim multimodalnim pristu pommo`e se posti}i 
zna~ajna regresija tumora uz prihvatljive popratne pojave, ~ime su kasniji kirur{ki postupci olak{ani ili ih se ~ak mo`e 
izbje}i u izabranih pacijenata.
U ovom preglednom ~lanku se podrobno iznose i raspravljaju najnovijipodaci o lije~enju raka rektuma i ideje o 
o~ekivanim budu}im istra`ivanjima.
KLJU^NE RIJE^I: rak rektuma, radioterapija, kemoterapija, multimodalno lije~enjenje
Carcinoma of the rectum, together with colon 
cancer, is the third most common malignancy. It 
appears frequently and at the same rate in women 
and men - 9.4% of newly detected patients and 7.9% 
of all causes of death from malignant disease.
The tumor bed is best defined by the distance 
from the ano-cutaneous border. Low positioned 
tumors pose a major challenge for successful treat-
ment. The cramped conditions between the bony 
structures of the pelvis reduce the likelihood of 
radical surgical removal, resulting in a high risk of 
local recurrence(1). Most of recurrences (85%) ap-
pear in first three years after the treatment(2). A 
multidisciplinary approach is required and rec-
ommended because of increased risk of local re-
currence and the treatment consequences which 
impair the quality of life (digestion, urination, sex-
ual life).
Research on the modalities and timing of ra-
diotherapy application departs from science-based 
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facts about better local control and prolonged sur-
vival in patients with T3-4 N+ tumors treated with 
adjuvant radiotherapy (NSABP R – 01(3) and 
NSABP R – 02(4)).
Based on the results of numerous studies, 
preoperative chemoradiotherapy was accepted by 
ESTRO in 2007 as a standard approach in the treat-
ment of patients with locally advanced disease 
(T3-4 N+). Preoperative treatment advantage is the 
reduction of the tumor up to the pathological com-
plete regression (in 10-25 % of patients). Radical 
local resection is facilitated and the likelihood of 
margin-free resection of tumor is increased. Post-
operative radiation is indicated in underestimated 
disease, should the pathologist findings show a 
stage higher than expected on the basis of imaging 
methods before surgery.
The essential component of the pathologist 
findings after the operation is the description of 
the circumferential edge (CRM margin). It repre-
sents the distance from the edge of the soft tissue 
preparation to the deepest penetration of tumor. 
Applied radiation benefit (reduced local recur-
rence rate) was briefly questioned by published 
results of only 8.2% local recurrence in patients 
treated with total mesorectal excision technique 
(TME). In another study from the Dutch Colorec-
tal Cancer Group, patients were randomized to 
preoperative pelvic irradiation at a dose of 5x5 Gy, 
or to the control group which was operated with-
out prior irradiation. It was shown that the rate of 
local recurrence after 5 years can be further re-
duced to 2.4 % even after TME (p = 0.001)(5).
According to the treatment results of GRCSG 
(German Rectal Cancer Study Group) in 823 pa-
tients with T3-4 or N+ rectal cancer, 5-year survival 
was 76% and 74% in the groups treated before or 
after the operation. Local recurrence was 6% in the 
group with neoadjuvantradiochemotherapy, and 
13% in the control group with adjuvant radioche-
motherapy (p=0.006). Significantly less grade 3 
and 4 side effects were found in the neoadjuvant 
group - 27% than in the adjuvant group - 40% 
(p=0.001)(6). The later published results of the same 
group (GRCSG) after a 11-year follow-up remained 
statistically significant in terms of local recurrence, 
with no impact on the survival length(7).
A similar comparison of pre- and postopera-
tive radiotherapy was carried out in a R-03 NSABP 
study(8) (National Surgical Adjuvant Breast and 
Bowel Project) which enrolled 267 patients. A sig-
nificantly better 5-year disease free survival (DFS) 
in preoperatively treated patients - 64.7 % versus 
53.4% (p=0.011) was observed after a median fol-
low-up of 8.4 years. There was no difference in 
overall survival (OS) of 74.5% vs. 65.6% (p=0.065).
Oxaliplatin administered together with 5-FU 
and leucovorin has significant activity in the treat-
ment of metastatic colorectal cancer. In primary 
rectal tumor treatment, adding of oxaliplatin does 
not contribute to its reduction in preoperative 
chemoradiotherapy, but increases the rate of acute 
side effects(9). In the ACCORD study, 598 patients 
with T3-4 N+ rectal cancer were randomized into 
groups of 45 Gy radiation delivered in 25 fractions 
with concomitant capecitabine or 50 Gy in 25 frac-
tions with concomitant capecitabine and oxalipla-
tin. After six weeks of chemoradiotherapy, TME 
was performed in 98% of patients in both groups. 
Complete pathological response was recorded in 
19.2% of patients having received oxaliplatin vs. 
13.9% in the control group (p=0.09), while grade 3 
or 4 toxicity was observed in 25% vs. 11% in the 
control group (p=0.001). There was no difference 
in anal sphincter preservation during surgery 
(75% vs. 78%).
Aschele et al. have conducted another simi-
larly designed study on the synergistic effect of 
oxaliplatin (STAR-01) in 747 patients in Italy(10). 
The pathological complete response rate in two 
randomized groups was the same (16%), and the 
rate of grade 3 and 4 adverse reactions was 24% in 
the group with oxaliplatin and 8% in the control 
group (p=0.001). Although the incidence of acute 
side effects has been monitored in most studies, 
they cause only short-term discomfort and resolve 
spontaneously or with symptomatic medication 
completely. Late side effects are more important 
(especially after radical surgery such as TME) be-
cause they impair the quality of life (anal sphinc-
ter incontinence, sexual dysfunction).
Somewhat conflicting results were reported 
from a study performed by Rodel et al. CAO/
ARO/AIO-04(11) where 1236 patients were ran-
domized into groups of preoperative radiotherapy 
with 5-FU or 5-FU with oxaliplatin. Significantly 
higher complete pathological regression rate was 
recorded (17% vs. 13%) in the control group 
(p=0.038) with no significant difference in the inci-
dence of grade 3 and 4 side effects.
By now, the application of oxaliplatin in the 
preoperative treatment setting with radiation is 
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not recommended outside of research protocols. It 
is necessary to wait and observe the results from 
these studies, particularly in terms of disease free 
survival (DFS).
Youn et al.(12) investigated the possible syner-
gistic effects of sorafenib administration together 
with radiation in the treatment of rectal cancer. 
They have treated three colorectal cancer cell lines 
and observed that most of the tumor cells stopped 
in the G2-M phase. The repair of DNA damage 
caused by radiation was delayed, while the rate of 
apoptosis in intestine glandular crypts in both 
groups was equally frequent.
Bujko et al.(13) compared the outcomes after a 
“short -course” (5 x 5 Gy) and “long -course” (28 x 
1,8 Gy) preoperative radiotherapy. The late compli-
cations rate did not differ significantly, respectively 
10% (“short -course”) vs. 7 % (“long -course”).
Many colorectal cancer characteristics were 
investigated with the intention to discover the 
possible factors which could predict regression 
and prognosis after preoperative radiotherapy: 
tumor volume, the serum level of carcinoembry-
onic antigen (CEA), tumor distance from the anal 
verge(13), the time elapsed between the completion 
of radiotherapy and the definitive surgery(14).
Gallon et al.(15) have studied 51 patients after 
preoperative chemoradiotherapy. The tumor bur-
den decreased in 54.9% and the complete histo-
logic regression was documented in 11.9%. The 
probability of tumor reduction was significantly 
associated with hemoglobin levels before treat-
ment > 12.0 g/dl (p=0.044) and relative lympho-
cytes number in the WBC before treatment >26% 
(p=0.022). Complete histologic regression was sig-
nificantly more frequently observed in patients 
with relative number of lymphocytes in the WBC 
>26% before treatment (p=0.023), absolute lym-
phocyte count > 1,634 x109/L (p=0.004), with clini-
cal findings of N- stage disease (p=0.018) and 
those with the hemoglobin level >12.0 g/dL be-
fore treatment. The authors conclude that the out-
come of preoperative treatment depends not only 
on the biological characteristics of the tumor, but 
also on the “micro-environment” in which the tu-
mor grows. In the literature, it is possible to find 
similar claims about the high level of circulating 
lymphocytes beneficial effect on the outcome of 
colorectal cancer treatment (15,16).
Derbel et al. failed to determine the outcome 
predictors after preoperative treatment by study-
ing KRAS, BRAF and PI3KCA mutations in rectal 
cancer. The observed variables in the group of 98 
patients were local recurrence and distant metas-
tases rate(17). They have concluded that further re-
search with a larger number of patients and great-
er statistical power is needed.
Complete histologic regression after preop-
erative treatment is associated with a significantly 
longer survival (KROG-09-01)(18), while the N+ 
lymph node finding after preoperative treatment 
is an unfavorable prognostic indicator regardless 
of the extent of the primary tumor regression(19). 
Meta-analysis of Lee et al.(20) clearly demonstrated 
that the partial regression of tumors is associated 
with a 50% improvement in the length of disease 
free survival (DFS) and should be considered as a 
favorable prognostic factor.
PET/CT imaging and the accumulation of 
FDG in the tumor tissue (SUV) could be a valuable 
predictor of tumor regression with 81% sensitivi-
ty, 100% specificity and 90% of overall reliability, 
as demonstrated by Bampo et al.(21). PET/CT has 
been performed twice: two and six weeks after 
standard preoperative radiotherapy in 31 patients. 
The complete histologic remission was accom-
plished in 30%. Early recordings showed no sig-
nificant regularity, but the results of the SUV re-
corded later were different between patients with 
complete and incomplete regression at the signifi-
cant level of p=0.006. Final decision on the role of 
PET/CT in determining the need of treatment 
continuation will be possible after future research 
with more patients. A reliable early assessment of 
insufficient tumor response would be valuable be-
cause of the possible intensification of radiothera-
py in these patients. Distinguishing complete from 
incomplete tumor regression after 6 weeks of ra-
diotherapy and before operation could lead to less 
radical or even avoided surgery (wait-and-see at-
titude). PET/CT could assist in screening patients 
and even determining of the optimal timing for 
accessing operation(22).
The optimal time for surgery after comple-
tion of preoperative radiotherapy is difficult to be 
determined unambiguously. On the basis of pub-
lished results, there are indications that an inter-
val longer than the generally accepted (6 weeks) 
could lead to higher rates of complete regression 
and more anal sphincter saving operations.
The argument for a “watch and wait” atti-
tude could result from the research that has al-
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ready begun. In the group of 70 patients with low 
rectal tumors staged T2-4 N0-2 M0Habr-Gama et al.
(23) 
applied 54 Gy of radiation plus 6 cycles of 5-FU/
LV chemotherapy, administered every 3 weeks. 
Complete clinical remission was observed in 68% 
of patients. Local recurrence occurred in this group 
in 17% during the first year, 10% in the second 
year, and 57% remained healthy after 5 years of 
follow-up. A significant contribution to the quality 
of life in these disease stages was the fact that 50% 
of the patients have never been operated. In the 
case of need timely “salvage” operation is always 
possible in carefully monitored patients.
An interesting Rapido study has just started 
with two randomized groups of patients: a control 
group with conventional preoperative therapy (50 
Gy with capecitabine) and an experimental group 
where after the introductory 5 x 5 Gy radiation fol-
low six cycles of chemotherapy with capecitabine 
and oxaliplatin. Upon the completion of preopera-
tive treatment, all the patients will be operated ac-
cording to the principle of TME. The monitored 
outcome will not only be the rate of local recur-
rence but especially the impact on overall disease-
free survival(24).
While it is scientifically proven that complete 
regression after preoperative treatment signifi-
cantly prolongs the disease free survival, the prog-
nostic value of partial regression is less reliable. 
Several authors propose their own ways of scor-
ing, eg. “tumor regression grade” (TRG) or “rectal 
cancer regression grade” (RCRG) in order to fa-
cilitate further research. These schemes, if proven 
their reliability, in the future may become more 
important than the current TNM system (intro-
duced before the preoperative treatment approach 
was invented). Until then the classification of tu-
mor characteristics according to the TNM system 
should mark the way data are collected (eg, the 
suffix “c”- clinically , “mr” - by NMR, “p” - histo-
logically, “ct” by CT scan). It is reliably to predict 
the course of illness in patients with complete tu-
mor regression or those with no response to pre-
operative treatment.
The first step in using the epidemiological 
data from large disease outcome registries was 
made by Bowles et al.(25). They have developed an 
interactive mathematical model of 5- and 10-year 
survival likelihood by using data on age, sex, race, 
tumor differentiation and the type of surgery per-
formed. Covariates were preoperative or postop-
erative radiotherapy, patients without treatment 
or stage IV disease. An online calculator was cre-
ated that can be found on www.mdanderson.org/
rectalcalculator. Assessment results are valuable, 
but orientation aid in predicting the course of dis-
ease and in the planning of further treatment or 
monitoring.
A further research subject could be the prog-
nostic significance of pelvic lymph node status af-
ter partial tumor regression, which will probably 
further stratify the same group of patients and con-
tribute to a better understanding of the disease.
Zhan et al.(26) were interested in the treatment 
outcome of shortened preoperative radiotherapy. 
Preoperative treatment lasting for 5-6 weeks in 
China is not the golden standard because of the 
radical surgery tradition and patients preference 
for being less absent far from home for treatment. 
After 30 Gy of applied radiotherapy in 10 fractions 
surgery followed within 14 days. The rate of com-
plete histologic regression in 101 patients was only 
5%, with 50% partial regressions. After five years 
5% of local recurrence was observed in the preop-
erative radiotherapy group and 18% in the control 
group (p=0.02). There was no significant periop-
erative complications increase.
The technique of radiation has recently not 
changed significantly. Radiation simulation as-
sumes prone positioning of the patient on the table 
top with a hole (“belly-board”) with a contrast 
view of the small intestine and the use of modern 
radiation planning tools such as 3-D and IMRT.
All the abovementioned findings were col-
lected and published after the debate in two new 
recommendations for the treatment of colorectal 
cancer, the European registry for the treatment of 
cancer (EURECCA)(26) and the American Society 
for colorectal surgery(27).
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